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Edited by Veli-Pekka LehtoAbstract CRSBP-1, a membrane glycoprotein, can mediate
cell-surface retention of secreted growth factors containing
CRS motifs such as PDGF-BB. CRSBP-1 has recently been
found to be identical to LYVE-1, a speciﬁc marker for lymphatic
capillary endothelial cells. The in vivo role of CRSBP-1/LYVE-1
is unknown. CRSBP-1-null mice are overtly normal and fertile
but exhibit identiﬁable morphological and functional alterations
of lymphatic capillary vessels in certain tissues, marked by the
constitutively increased interstitial-lymphatic ﬂow and lack of
typical irregularly-shaped lumens. The CRSBP-1 ligands
PDGF-BB and HA enhance interstitial-lymphatic ﬂow in wild-
type mice but not in CRSBP-1-null animals.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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lymphatic ﬂow1. Introduction
Autocrine and paracrine regulation of cell growth are impor-
tant mechanisms by which growth factors stimulate growth
and migration of targeted cells in angiogenesis, organogenesis,
embryonic development and tissue remodeling in response to
injury or aging [1]. In autocrine regulation, cell-surface reten-
tion provides an eﬃcient mechanism for a secreted growth fac-
tor that is often secreted in relatively small amounts to interact
with its receptor at the cell surface [1–7]. Without cell-surface
retention, a larger amount of growth factor would need to
be secreted in order to accumulate in the extracellular com-
partment or the medium to reach a concentration that allows
high-aﬃnity binding to its receptor. In paracrine regulation,
cell-surface retention orchestrates release of growth factor in
a coordinated and directional manner to recruit target cells
(via chemotaxis) to spatially orient cell growth and diﬀerentia-*Corresponding authors. Fax: +1 314 977 9205 (S.S. Huang,
J.S. Huang).
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platelet-derived growth factor-AA (PDGF-AA), PDGF-BB,
placenta growth factor and vascular endothelial cell growth
factor-A/C/D (VEGF-A/C/D), possess cell-surface retention
sequence (CRS) motifs and exhibit cell-surface retention dur-
ing secretion [3–6,8–10]. These motifs contain clustered basic
amino acid residues (Arg, Lys and His) and are evolutionarily
conserved.
CRS binding protein-1 (CRSBP-1) is the only protein
known to interact with peptides containing the CRS motifs
of PDGF-BB and VEGF-A with high aﬃnity (Kd =  1 nM)
[11]. It has been shown to mediate cell-surface retention of
the simian sarcoma virus (SSV) oncogene v-sis gene product
(PDGF-BB) and insulin-like growth factor-binding protein-3
(a CRS-containing growth regulator) in SSV-transformed
ﬁbroblasts and HI299 cells co-expressing CRSBP-1 and
IGFBP-3 [12]. CRSBP-1 mediates ligand-dependent internali-
zation and recycling at the cell surface, allowing eﬃcient
interaction of growth factor and receptor in cells expressing
these three molecules [11–13]. CRSBP-1 is a 120-kDa type I
membrane disulﬁde-linked dimeric protein [11,12]. Bovine
CRSBP-1 cDNA encodes a 322-amino acid residue protein
[12]. The deduced amino acid sequences of human and murine
CRSBP-1 cDNAs exhibit 61% and 56% identity with bovine
CRSBP-1 cDNA, respectively [12]. These two sequences were
identiﬁed independently and named LYVE-1 (lymphatic vessel
endothelial HA receptor-1) [14,15]. LYVE-1, which was cloned
using CD44 sequence homology cloning, is a hyaluronic acid
(HA)-binding membrane glycoprotein [14,15]. We found that
expressed CRSBP-1 possesses distinct dual ligand (CRS motif
and HA) binding activity and that CRSBP-1 overexpression
enhances autocrine regulation of cell growth stimulated by
the v-sis gene product and other growth regulators containing
CRS [12].
The biological properties of CRSBP-1 have been studied
mainly using cultured ﬁbroblasts [11–15], but its role in intact
animals has not yet been fully deﬁned. The known ligands of
CRSBP-1, including PDGF-BB and the VEGF family, are
known to be involved in the development of the vascular
and lymphatic systems [16,17]. PDGF-BB is known to be a
growth factor for either vascular or lymphatic capillary endo-
thelial cells. The ﬁnding that CRSBP-1 and LYVE-1 are iden-
tical suggests a potential role of CRSBP-1 in the function ofblished by Elsevier B.V. All rights reserved.
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ized to the luminal and abluminal faces of lymphatic vessels
and has been used as a speciﬁc marker for lymphatic endo-
thelium [14,15,18]. However, the functional role of LYVE-1
in lymphatic vessels remains unknown. In this communication,
we demonstrate that CRSBP-1/LYVE-1 may mediate ligand-
sensitive control of interstitial-lymphatic ﬂow and its genetic
ablation results in loss of such control and constitutively in-
creased interstitial-lymphatic ﬂow.2. Materials and methods
2.1. Construction of the targeting vector
The targeting vector [19] was constructed to remove parts of exon II,
intron II, exon III and part of intron III of the CRSBP-1 gene and also
to create a frame shift in the gene product, which contained 3 kb and
4.5 kb of 5 0 and 3 0 homology of the CRSBP-1 gene. The 5 0 3-kb frag-
ment, which covered parts of exon I, intron I, and a part of exon II,
was obtained by using an expanded high ﬁdelity PCR kit from Roche
with primer 1 (5 0-AGGCACCCAGTCCAAGGTGCCGACCTC-3 0)
in exon I and primer 2 (5 0-CACAAGGGCAACGCCCATGATTC-
TGCATG-3 0) in exon II and SVJ 129 mouse genomic DNA as tem-
plate. The PCR conditions were: 94 C, 1 min; 50 C, 1 min; 68 C,
10 min for 35 cycles and extension at 72 C for 8 min. The PCR prod-
uct of 3 kb was cloned into PCR-XL Topo vector (Invitrogen). The
EcoRI fragment (3 kb) was ligated to the EcoRI site of pPNT-Cass
Lox A vector (9.3 kb). The sense orientation was determined by
DNA sequencing. The 3 0 7 kb fragment was obtained by using primer
3 (5 0 CAAAGCCTATTGCCACAACTCATCCG-3 0) in exon III and
primer 4 (5 0 GCCTCGTGTGCACCTTCTCCACTCTC-3 0) in exon
VI and cut with Xho and NotI. This 7 kb fragment was cloned into
PCR-XL Topo vector. A 4.5 kb Xhol–NotI fragment was ligated to
XhoI/NotI digested sites of the pPNT-Cass Lox A vector which already
contained the 5 0 3 kb fragment.
2.2. Generation of CRSBP-1-null (CRSBP-1/) mice
The targeting vector (25 lg) was linearized with Xhol digestion and
electroporated into the 129Sl/SV-xP mouse-derived embryonic stem
(ES) cells. The electroporation and generation of chimeric mice was
done by the Yale University Gene Targeting Service. Heterozygote
mice (a total of 12) were mated to produce homozygous knockout
(CRSBP-1/) mice. CRSBP-1/ mice were backcrossed for 10 gener-
ations onto the C57/BL/6 genetic background. Identical results were
obtained on the mixed and inbred background. Genotyping was per-
formed by PCR and Southern blot analysis of DNA obtained by tail
biopsies at 10 days. Mice were genotyped by PCR using the upstream
primer (in intron I near exon 2) with the downstream primer (in exon
3) for the wild-type allele and with the downstream primer (in intron
III) for the disrupted allele, respectively. Mice were also genotyped
by Southern blot analysis using a 200 bp sequence outside of the tar-
geting vector probe. Tail DNA of wild-type and mutant mice were di-
gested with EcoRI, transferred to membranes (Stratagene) and
subjected to Southern blot analysis according to standard procedures.
CRSBP-1- null mice (CRSBP-1/) have been included in the Induced
Mutant Resources at the Jackson Laboratory, Bar Harbor, ME 04609
(Stock # 006221,B6. 129Sl-XlkdlÆtmJhuaæ/J).
2.3. Southern blot analysis of genomic DNA from wild-type
(CRSBP-1+/+), heterozygote (CRSBP-1+/) and homozygote
(CRSBP-1/) mice
EcoRI-digested genomic DNA isolated from tail tissues of wild-type
(+/+), heterozygous (+/), and homozygous (/) mice were blotted
and probed with the 32P-labeled PCR fragment (200 bp). A 5.4 kb
restriction fragment was evident from the wild-type allele and a
3.9 kb fragment from the disrupted allele.
2.4. Germline transmission of the CRSBP-1/ mutation
The gene targeting event was identiﬁed by Southern blot analysis
with EcoRI digested genomic DNA and the probe shown in Fig. 4A.
Germline transmission was conﬁrmed by Southern blot analysis of tail
DNA of the Fl oﬀspring from cross-breeding of chimera with wild-typeC57BL/6 mice. Genotypes of wild-type (+/+) and homozygous (/)
mice were identiﬁed by the presence of PCR product speciﬁc to either
the wild-type or mutant allele.
2.5. RNA preparation and RT-PCR
Wild-type and CRSBP-1/mice were euthanized by CO2 inhalation
and liver tissues were removed immediately and frozen in liquid nitro-
gen. The liver RNA was extracted using RNAzole B (Tel-Test, Tri-
endswood, TX). Brieﬂy, 2 ml of RNAzole B solutions was added to
1 g of liver tissue and homogenized with a Polytron homogenizer;
RNA was extracted with chloroform and precipitated with isopropyl
alcohol. An aliquot of RNA was run on formaldehyde gel to check
the integrity of the RNA. RT-PCR was performed with 2 lg of total
RNA from wild-type and knockout mice using the RT-PCR kit with
platinum Taq from Life Technology. The primers used to amplify
the wild-type RNA were primers P5 (5 0-AGAA-CTCTCCATC-
CAGCTTGGTG-3 0) and P8 (5 0-GACACCTTTGCCATTGTTCC-
CACACC-3 0). The primers used to amplify exon I and exon IV of
the knockout mice RNA were primer P5 and primer P9 (5 0-AA-
CACGGGGTAAAATGTGGTAACG-30). Primers speciﬁc for b-
actin were used in control reactions.
2.6. Semi-quantitative analysis of interstitial-lymphatic ﬂow
To analyze the interstitial-lymphatic ﬂow in the tissues of wild-type
and CRSBP-1/ mice, 20 ll of 8 mg/ml ﬂuorescein isothiocynate
(FITC)-dextran (average MW 2000000; Sigma) with and without
PDGF-BB (12.5 lg/ml), HA (250 lg/ml) or both in phosphate-buﬀered
saline (PBS) was injected intradermally by hand into the tails of mice
(ﬁve female mice for each group). The progressive diﬀusion of high
molecular-weight FITC-dextran (which is taken up by lymphatic cap-
illary vessels in the tissue near the injection site) was examined over
time by monitoring ﬂuorescence near the injection site with a UV light.
The ﬂuorescence intensity was determined by densitometry following
photography. The relative ﬂuorescence intensity in mice injected with
PBS was taken as 100% (control). The interstitial-lymphatic ﬂow anal-
ysis appeared to be semi-quantitative and speciﬁc. HA induced a
decrease in the ﬂuorescence near the injection site (10 min after
injection) in a dose-dependent manner. HA at 25 and 250 lg/ml
decreased the ﬂuorescence intensity to 52 ± 2 (n = 5) and 33 ± 10
(n = 5), respectively. In the experiments to show the speciﬁcity of the
analysis, both CRSBP-1/ and the wild-type mice exhibited similar
diﬀusion rates of the low molecular-weight, hydrophobic and tissue-
permeable ﬂuorescent compounds ﬂuorescein (MW 332) and hymecro-
mone (MW 176) injected intradermally into the tails of these animal.
These compounds diﬀused rapidly within the tissue. This suggests that
increased egress of the ﬂurorescent compound near the injection site is
selective according to the MW of the agent chosen and consistent with
a sieving process. Furthermore, PDGF-BB and HA each did not sig-
niﬁcantly aﬀect the diﬀusion rates of these small MW compounds that
were injected intradermally in wild-type mice.2.7. Immunohistochemistry
Tissues from wild-type and CRSBP-1/ mice were ﬁxed in 10%
neutral buﬀered formalin for 18 h and then subjected to histologic pro-
cessing. At the time of immunostaining, tissue sections were deparaﬀ-
inized and hydrated. The sections were pretreated with H2O2 (0.3%)
for 5 min and blocked with 10% goat serum plus 5% bovine serum
albumin (BSA) in TBS (Tris-buﬀered saline) for 30 min. Sections were
incubated with a rabbit serum against the C-terminal tail of bovine
CRSBP-1 [12] (1:100 dilution) at room temperature for 30 min, rinsed
with TBS, incubated with horseradish peroxidase (HRP)-labeled poly-
mer (DAKO En Vision System) for 30 min, developed with diam-
inobenzidine (DAB), counterstained with hematoxylin, dehydrated
sequentially with 70%, 95% and 100% ethanol and clear xylene, then
mounted on coverslips.
For staining with antibodies to podoplanin, tissue sections were
incubated with hamster anti-mouse podoplanin (AngioBio Co., Del
Mar, CA). After washing, the sections were incubated with biotin-con-
jugated goat anti-hamster IgG (Southern Biotech, Birmingham, AL)
(1:1000) for 30 min and washed three times with PBS. Sections were
treated with HRP-streptavidin (1:1000) (Sigma) for 30 min. After
washing three times with PBS, the sections were developed with
DAB solution (1 mg/ml in 5 mM sodium phosphate buﬀer, pH 7.4)
for 5 min.
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Livers (0.7–0.9 g) from wild-type and CRSBP-1/ mice were
washed with buﬀer A (50 mM Tris–HCl, 1 mM EDTA, pH 7.4) twice
to remove blood. The liver was homogenized in buﬀer A containing
1 mM phenylmethylsulfonyl ﬂuoride (PMSF) (5 ml per gram tissue)
with a tissue homogenizer. The homogenates were centrifuged at
2000 rpm for 10 min to remove tissue debris and recentrifuged at
15000 rpm for 30 min to obtain crude membranes. The crude mem-
branes were washed with buﬀer A, solubilized in 1 ml buﬀer B
(50 mM Tris–HCl, 3 mM EDTA, 1 mM PMSF and 1% Triton X-
100) and centrifuged at 14000 rpm for 10 min. The supernate was then
rotated with wheat germ lectin (WHA)-agarose gel (volume = 40 ll)
overnight. The WHA gel was washed three times with buﬀer B and
eluted with 50 ll of buﬀer B containing 0.4 M N-acetylglucosamine.
The eluents were subjected to 7.5% SDS–polyacrylamide electrophore-
sis (SDS–PAGE), electrophoretic transfer to polyvinylidene ﬂuoride
(PVDF) membranes and immunoblot analysis with antiserum to
CRSBP-1 [11].
2.9. Determination of the wet-to-dry weight ratios of tissues
Tissues (heart, liver, kidney and spleen) frozen and lyophilized with
a Virtis lyophilizer (Freezemobile) for 48 h. The dried tissues were then
weighed (as dry weight). The wet-to-dry weight ratios of the tissues or
tumors were determined.
2.10. Statistical analysis
The values represented the mean ± standard deviation (S.D.). Two-
tailed unpaired Student’s t-test was used to determine the signiﬁcance
of diﬀerences between groups, P < 0.05 was considered signiﬁcant.3. Results
3.1. Generation of CRSBP-1/ mice
To investigate the role of CRSBP-1 in vivo, we determined
the structure of the mouse CRSBP-1 gene and generated1                                      2 3                    R
1                                      2                      
R
Wild Type
Targeting Vector
Recombinant
Lo
x 
P(
72
0)
N
eo Po
lI
I p
ro
m
ot
or
1                                       2                      
R
1                                       2                      
R
N
eo
Po
lI
I p
ro
m
ot
or
Lo
x 
P(
72
0)
After excision 
of  Neo gene
R
R
R
probe
TK
3.9kb
5.4kb
A
B
C
D
Fig. 1. Gene targeting of the murine CRSBP-1 locus. The mouse CRSBP-1 al
introns (A). A targeting vector (pPNT-Cass Lox A) was constructed to delet
contains a cassette ﬂanked by loxP elements, including sequences conferrin
sequences encoding cre recombinase (Cre) [under the direction of a testis-
symbolized as numbered rectangles. The recombinant allele in ES cells and the
respectively. The black horizontal bar indicates the location of the probe used
type (A) and disrupted (D) alleles after digestion with EcoRl (R) are shownCRSBP-1/ mice. The entire genome structure of the mouse
CRSBP-1 gene was elucidated based on mouse CRSBP-1
cDNA using the mouse genome sequence database. The
CRSBP-1 gene resides on mouse chromosome 7. As shown
in Fig. 1 A, the mouse CRSBP-1 allele consists of 6 exons,
which all contain coding sequences, and 5 introns. The signal
sequence and the ﬁrst four amino acid residues of the N-termi-
nal polypeptide are encoded by exon 1. The transmembrane
domain is encoded by exon 5 and the cytoplasmic domain is
encoded by exon 6.
To generate the CRSBP-1/ mutation in ES cells, we de-
signed a replacement-type targeting vector containing a cas-
sette ﬂanked by loxP elements [19]. The cassette includes
sequences conferring neomycin resistance (Neo) as well as tes-
tes-speciﬁc angiotensin-converting enzyme promoter (tACE
promoter) sequences that direct expression of cre recombinase
(Cre) in the male germ line only (Fig. 1B). The targeting cas-
sette vector was constructed to remove part of exon 2, intron
2, exon 3 and part of intron 3 and also to create a frame shift
in the gene product (Fig. 1A and B). The targeting vector was
linearized with Xhol digestion and electroporated into 129Sl/
Sv-p+ mouse-derived ES cells. After 24 h, the cells were placed
under positive/negative selection with 200 lg/ml G418 and
2 lM ganciclovir for 6 days. Clones resistant to this double
selection were isolated and analyzed by Southern blot analysis
using a probe for a sequence which is located in exon 1 but
outside of the targeting vector (as indicated by the black hor-
izontal bar in Fig. 1A) and a probe for a sequence which is lo-
cated in exon 6 but outside of the targeting vector. Southern
blot analysis was used to identify the homologous recombinant
allele (Fig. 1C) ES line. Two independent, targeted ES clones
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females. The resulting Neo-excised allele (Fig. 1D) heterozygote
mice (a total of 12) were mated to produce homozygous
knockout (CRSBP-1/) mice.
CRSBP-1/ mice were initially obtained on a mixed
C57BL/6/129 background (n = 200) and backcrossed for 10
generations onto the C57BL/6 genetic background. Identical
results were obtained on the mixed and inbred background.
CRSBP-1/ mice appeared overtly normal and were fertile
with normal litter sizes. No gross abnormalities (e.g., body
weight and relative organ weight, and wet-to-dry weight ratios
of tissues such as kidney, liver, lung, heart and spleen) were ob-
served over their entire life span, with the oldest animal close5000
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tected by allele-speciﬁc PCR (Fig. 2Aa). The wild-type speciﬁc
band of 500 bp is only present in wild-type mice (Fig. 2Aa,
lane 1) whereas the 400 bp band is speciﬁc for the disrupted
allele (Fig. 2Aa, lane 2). The disruption of the CRSBP-1 gene
was conﬁrmed by Southern blot analysis, since the wild-type
speciﬁc band at 5.4 kb is replaced by a band at 3.9 kb in
CRSBP-1/ mice (Fig. 2Ab). The disruption of the CRSBP-
1 gene was further conﬁrmed by the absence of the wild-type
speciﬁc RT-PCR band in CRSBP-1/ mice. As shown in
Fig. 2B, the wild-type RT-PCR speciﬁc band at 419 bp (lane
1) is absent in CRSBP-1/ mice (lane 2). This suggests that
exon 3 is deleted in CRSBP-1/ mice, as expected. In another-5.4 kb
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ucts with the predicted sizes (268 bp and 534 bp) were detected
in CRSBP-1/ and wild-type mice, respectively (data not
shown). The absence of CRSBP-1 protein in CRSBP-1/mice
was proven by Western blot analysis with a polyclonal anti-
body directed against the cytoplasmic tail of CRSBP-1 [12].
As shown in Fig. 2C, CRSBP-1 was detected in the liver of
wild-type (CRSBP-1+/+) mice (lane 1) whereas it was not de-
tected in the liver of CRSBP-1/ mice (lane 2).
3.2. Constitutively increased interstitial-lymphatic ﬂow and
lack of typical irregular-shaped lumens of lymphatic
capillary vessels in CRSBP-1/ mice
Although CRSBP-1/ mice were overtly normal, in order
to examine lymphatic capillary vessels, we performed compar-B
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a speciﬁc antibody to CRSBP-1 [11,12]. Lymphatic vessels in
CRSBP-1/ mice were identiﬁed based on the morphology
and speciﬁc location of lymphatic vessels in certain tissues
(e.g., intestine and liver) and also by immunohistochemical
analysis of all tissues examined using antibodies to podopla-
nin. Among tissues examined (liver, intestine, lung, ovary,
uterus, vagina, cervix, salivary gland, skin, kidney, brain and
foot pad), the liver and intestine exhibited diﬀerences in
lymphatic morphology between CRSBP-1/ and wild-
type mice most clearly. For tissues with abundant connective
tissue (e.g., skin) and other tissues, no clear morphologicalA
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mice, perhaps due to limited distensibility of such tissues.
However, the typical irregular shapes and/or smaller sizes of
lymphatic vessels were detected only in a fraction of lymphatic
vessels in the liver and intestine of wild-type and heterozygote
mice. In the portal triad of the liver of CRSBP-1/ mice, lym-
phatic vessels had distended lumens marked by larger or ex-
panded shapes and did not have collapsed irregular shapes
and/or smaller sizes seen in wild-type mice (Fig. 3E/F versus
A/B). The lymphatic vessels in the liver of CRSBP-1/ and
wild-type mice were also identiﬁed by immunostaining using
antibodies to CRSBP-1 and podoplanin (Fig. 3C/G and D/
H, respectively). However, bile ducts in portal triads were also
stained by antibody to podoplanin (Fig. 3D and H). In the
intestine of CRSBP-1/ mice, lymphatic vessels had altered
morphology, with distended lumens marked by extended orA
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Fig. 4. Morphological alterations of lymphatic vessels in the intestine of CRS
embedded intestine tissue sections from wild-type (A) and CRSBP-1/ (B,C
podoplanin (C) and HRP + DAB (magniﬁcation, 200·). The lymphatic ves
positively stained (A). In the intestine of CRSBP-1/mice, the lymphatic ves
stained by antibodies to podoplanin (C).  indicates the location of lymphati
shape in CRSBP-1/ mice (B,C). By contrast, they have various sizes and ch
the small-sized or irregularly-shaped vessels (A).rounded shapes as compared to smaller or typically collapsed
irregular shapes observed in wild-type mice (Fig. 4B and C ver-
sus A). In contrast to wild-type and heterozygote mice, no col-
lapsed irregular shapes of lymphatic vessels were detected in
the liver and intestine of any CRSBP-1/ mice examined
(12 mice; female and male, 6–8 weeks old).
The distended lumens and the lack of typical irregularly-
shaped lumens of lymphatic vessels in CRSBP-1/ mice
suggested that the lumens of lymphatic capillaries may be con-
stitutively extended and permit rapid transit of macromole-
cules from the interstitium to lymphatic vessels in the whole
animal system. To test this possibility, we intradermally in-
jected FITC-dextran (average MW 2000000) with and with-
out PDGF-BB (12.5 lg/ml) and/or HA (250 lg/ml) into the
tails (at a site 2 cm from the tail tip) of CRSBP-1/ and
wild-type (CRSBP-1+/+) mice. We then compared the decreaseCRSBP-1+/+
CRSBP-1-/-
CRSBP-1-/-
*
*
*
*
*
*
**
*
BP-1/ mice. Immunohistochemical stains of formalin-ﬁxed, paraﬃn-
) mice, which were performed using antiserum to CRSBP-1 (A,B) or
sels in the intestine (duodenum) of wild-type (CRSBP-1+/+) mice are
sels in similar locations are identiﬁed by morphological analysis (B) and
c vessels. Lymphatic vessels are, in general, larger and have a distended
aracteristic irregular shapes in wild-type mice (A). The arrow indicates
CRSBP-1+/+
CRSBP-1-/-
A
PDGF-BB
HA+PDGF-BB
CRSBP-1 +/+
Control
PDGF-BB
B
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Control
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control
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Fig. 5. Inability of CRSBP-1 ligands to enhance interstitial-lymphatic ﬂow in CRSBP-1/ mice. Twenty microliter of FITC-dextran (8 mg/ml) were
intradermally injected into the tails of wild-type (CRSBP-+/+) and CRSBP-1/mice (A). CRSBP-1+/+ and CRSBP-1/mice were also intradermally
injected with FITC-dextran ± PDGF-BB (12.5 lg/ml) and/or HA (250 lg/ml) (B–D). After 10 min, photographs were taken in the presence of UV
light. The arrows indicate the injection site of FITC-dextran. The bracket indicates the location of FITC-dextran ﬂuorescence. The other bright areas
are due to the light reﬂection of hair. The FITC-dextran ﬂuorescence vanished more rapidly near the injection site in CRSBP-1/ mice than in
CRSBP-1+/+ mice (A). In CRSBP-1+/+ mice, PDGF-BB and HA each (but not together) caused diminished ﬂuorescence near the injection site.
PDGF-BB was more eﬀective than HA (B,C). In CRSBP-1/ mice, injection of PDGF-BB and HA (together or alone) was unable to diminish
ﬂuorescence (D).
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in both groups. High molecular-weight and tissue-imperme-
able FITC-dextran enters lymphatic capillary vessels from
the interstitial space after being injected into tissue and is a
standard lymphatic imaging agent. As shown in Fig. 5A,
FITC-dextran ﬂuorescence at the injection site diminished
more rapidly in CRSBP-1/ mice than in wild-type mice.
By 10 min after injection, the ﬂuorescence of FITC-dextran
near the injection site was 30 ± 5% in CRSBP-1/ mice as
compared with wild-type mice (arbitrarily scored 100%). In
CRSBP-1+/+ mice, PDGF-BB and HA caused diminished ﬂuo-
rescence near the injection site at 10 min, but PDGF-BB was
more eﬀective than HA at their optimal doses (Fig. 5B and
C). PDGF-BB decreased the ﬂuorescence intensity to
20 ± 5% (n = 5) of control whereas HA decreased the ﬂuores-
cence intensity to 40 ± 10% (n = 5) of control (Fig. 5B).
Administration of PDGF-BB and HA together did not de-
crease ﬂuorescence as compared to controls (Fig. 5C). The
mechanism for this unknown, but HA is known not to aﬀect
PDGF-BB binding to CRSBP-1 [12]. However, PDGF-BB
and HA, either alone or together, did not accelerate the egress
of FITC dextran in CRSBP-1/ mice (Fig. 5D). These results
suggest that CRSBP-1 may mediate ligand-sensitive control of
interstitial-lymphatic ﬂow and that loss of CRSBP-1 results in
constitutively increased interstitial-lymphatic ﬂow which is
insensitive to CRSBP-1 ligand enhancement.4. Discussion
Under normal circumstances, lymphatic capillaries are gener-
ally collapsed and closed. An increase of the interstitial ﬂuidpressure caused by an increased ﬂuid volume in tissue is gener-
ally thought to stretch the ﬁbers and expand the lymphatic
lumen [20–22]. This causes the intercellular junctions and blind
ends of lymphatic capillary vessels to open, thus increasing
interstitial-lymphatic ﬂow [20]. However, the exact molecular
mechanisms involved in controlling the opening of lymph
drainage and lymphatic ﬂow in the interstitium remain un-
known [21]. Our ﬁnding of CRSBP-1 ligand-induced enhance-
ment of interstitial-lymphatic ﬂow in wild-type mice but not in
null mice suggests that CRSBP-1 may mediate ligand-sensitive
control of interstitial lymphatic ﬂow and that its genetic abla-
tion may result in loss of such control and constitutively
increased interstitial-lymphatic ﬂow. We propose a model
(Fig. 6), which is modiﬁed from the published model [20], for
the role of CRSBP-1 in controlling interstitial-lymphatic ﬂow
in wild-type mice and loss of such control in CRSBP-1/mice.
In lymphatic capillary vessels of wild-type mice, lymphatic
endothelial cells have overlapping intercellular junctions that
generate irregularly shaped lumens (partially closed or closed)
(Fig. 6A). CRSBP-1 may be involved in the formation of the
cellular extension and overlapping intercellular junctions.
CRSBP-1 ligands PDGF-BB and HA each may cause contrac-
tion of lymphatic endothelial cells, resulting in opening of these
junctions in the lymphatic capillaries, thus increasing intersti-
tial-lymphatic ﬂow (Fig. 6B). In CRSBP-1/ mice, lymphatic
capillary endothelial cells appear to assume the contracted con-
ﬁguration and lose the ability to form cellular extension, pulling
apart the endothelial cells, expanding the lumens of lymphatic
capillary vessels, increasing interstitial-lymphatic ﬂow and
being insensitive to ligand-induced contraction (Fig. 6B).
CRSBP-1 ligands such as HA and PDGF-BB may function
as mediators or sensors controlling opening of lymphatic
Bfluid
fluid
A
anchoring filaments
collagen and 
elastin fibers
CRSBP-1 ligands or CRSBP-1-null mutation
Fig. 6. A model for CRSBP-1-mediated ligand-sensitive control of interstitial-lymphatic ﬂow in wild-type mice and loss of such control in CRSBP-
1/ mice. Lymphatic capillary vessels, which have overlapping intercellular junctions that are formed by the extensive superimposition of adjacent
lymphatic endothelial cells and generate collapsed irregularly-shaped lumens (closed or partially closed conﬁguration), are ﬁrmly attached to the
collagen and elastin ﬁbers in adjacent tissues by anchoring ﬁlaments [20] (A). CRSBP-1, a membrane glycoprotein, may be involved in the formation
of the cellular extension and overlapping intercellular junction of lymphatic endothelial cells. In wild-type mice, CRSBP-1 ligands induce contraction
of lymphatic endothelial cells. In CRSBP-1-null mice, lymphatic endothelial cells assume the contracted conﬁguration. These cause the intercellular
junctions and blind ends of lymphatic capillary vessels to open, thus increasing interstitial-lymphatic ﬂow (B). The thin arrows indicate the direction
of cellular contraction in CRSBP-1/ mice or when CRSBP-1 ligands are present in CRSBP-1+/+ mice (B).
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stitial space of tissues and in lymphatic ﬂuid [23,24], we
hypothesize that HA is a regulator of interstitial-lymphatic
ﬂow. CRSBP-1 is localized to both the luminal and abluminal
faces of lymphatic capillary endothelial vessels. The diﬀerence
between the HA concentrations in the interstitial space (HA-
out) and in the lymphatic capillary lumen (HAin) [23,24] may
be an important factor controlling the opening of lymphatic
capillary vessels. When HAout is higher than HAin, the lym-
phatic vessel dilates and becomes more porous as observed
in lymphatic vessels of CRSBP-1/ mice (Fig. 6B). When
the HAout is lower than HAin, the reverse occurs (Fig. 6A).
PDGF-BB is believed to play a role in the control of tissue
interstitial ﬂuid pressure (IFP) [25]. In animal models,
PDGF-BB was shown to normalize dermal IFP, which had
been lowered by inducing anaphylaxis or inhibiting the aIIbI
integrin function [26]. Treatment with a PDGF receptor kinase
inhibitor or a PDGF-BB aptamer antagonist appeared to de-
crease interstitial hypertension and increase capillary-to-inter-
stitium transport in implanted colonic carcinomas in rats
[27]. This led to the suggestion that PDGF-BB is involved in
creating and/or sustaining a high tumoral IFP. However, the
recent observation that blockade of PDGF b-type receptoractivity leads to ﬂuid accumulation or edema, implies the
involvement of PDGF-BB in facilitating interstitial-lymphatic
ﬂow [28]. Here, we demonstrate that PDGF-BB can enhance
interstitial-lymphatic ﬂow in wild-type mice but not in
CRSBP-1-null mice. This result suggests that CRSBP-1 may
mediate PDGF-BB-enhanced interstitial-lymphatic ﬂow. This
result is also consistent with previous reports that mice deﬁ-
cient in PDGF-BB exhibit interstitial edema [29] and that
blockage of PDGF-BB-induced signaling causes edema in hu-
man patients [28].
Two lines of evidence suggest that CRSBP-1 plays a role in
regulating the function of lymphatic endothelium. These in-
clude: (1) CRSBP-1 ligands PDGF-BB and HA enhance inter-
stitial-lymphatic ﬂow in wild-type mice but not in CRSBP-1/
mice, and (2) PDGF-BB and VEGF-A peptides containing the
CRS motifs of PDGF-BB and VEGF-A [11], like intact
PDGF-BB and VEGF-A, enhance interstitial-lymphatic ﬂow
in wild-type mice (unpublished results). These peptides do
not interact with the PDGF b-type and VEGF-A receptors,
respectively [11]. The importance of CRSBP-1 in mediating
the ligand-sensitive control of interstitial-lymphatic ﬂow is fur-
ther supported by the observation of altered morphology of
lymphatic capillary lumens in CRSBP-1/ mice. We observed
S.S. Huang et al. / FEBS Letters 580 (2006) 6259–6268 6267distended lumens and the lack of typical irregularly-shaped lu-
mens of lymphatic capillary vessels in certain tissues such as
liver and intestine (in these null mice). This may be due to
the fact that the lymphatic capillary vessels are present in the
areas where connective tissues are not abundant (e.g., liver
and intestine). The morphology of lymphatic capillary vessel
lumens is strongly inﬂuenced by the surrounding connective
tissues (which cause tissue compression) and staining and ﬁxa-
tion procedures used in immunohistochemical staining. Even
in the duodenum of wild-type mice, only a fraction of the lym-
phatic vessels exhibit typical irregular shapes of lumens. It is
important to note that none of the lymphatic vessels examined
in the liver and duodenum of CRSBP-1/ mice exhibited col-
lapsed irregular shapes of lumens.
CRSBP-1 exhibits dual ligand (CRS motif and HA) binding
activity. The CRS motif binding activity of CRSBP-1 is be-
lieved to be involved in cell-surface retention of growth factors
in the PDGF superfamily and autocrine and paracrine growth
stimulated by these growth factors [11–13]. The physiological
role of the CRS motif binding activity of CRSBP-1 in intact
animals is unknown. CRSBP-1/ mice are grossly normal
but exhibit identiﬁable microscopic morphological and func-
tional alterations of lymphatic capillary vessels. This suggests
that other proteins, such as membrane-bound proteoglycans
[30,31] that can bind the CRS motifs can substitute for the
function of the CRS motif-binding activity of CRSBP-1 to
mediate autocrine and paracrine stimulation of cell growth
during hemangiogenesis and lymphangiogenesis in the devel-
oping mouse, but no other known proteins can replace
CRSBP-1 in mediating the interstitial-lymphatic ﬂow-enhanc-
ing activity of PDGF-BB in CRSBP-1/ mice. The CRS
motif-binding activity (or PDGF-BB binding activity) of
CRSBP-1 appears to be involved in the control of lymphatic
vessel opening. The CRSBP-1 ligands (e.g., PDGF-BB) may
serve as mediators for distending the lumens of lymphatic cap-
illary vessels and enhancing interstitial-lymphatic ﬂow. Thus,
the null mutation of CRSBP-1 only reveals a defect in the
ligand-sensitive control, resulting in constitutively increased
interstitial-lymphatic ﬂow (Fig. 6B).
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